[ヘリコバクター・パイロリの根絶のための高用量二重療法:有効性と安全性]
N V Bakulina1, V A Ponomarenko1, A S Kerimova1
1Mechnikov North-Western State Medical University.
Terapevticheskii arkhiv
|August 30, 2025
まとめ
ヘリコバクター・パイロリを根絶するための高用量二重療法 (HDDT) の有効性は低かった. リバミピドをHDDTに追加することで,有効な治療法としてその可能性が示された.
科学分野:
- 胃腸内科
- 感染症
- 薬理学について
背景:
- ヘリコバクター・パイロリ感染に関する展望的オープン比較介入研究.
- 高用量二重療法 (HDDT) の有効性と安全性を調査した.
研究 の 目的:
- HDDTの有効性と安全性を評価する. パイロリの根絶
- HDDTにリバミピドを添加すると,根絶率に与える影響を評価する.
主な方法:
- HDDT,レバミピドによるHDDT,ビスムートによる従来のトリプルセラピー.
- 治療期間は14日でした.
- 治療後4~6週間で有効性を評価し,安全性および遵守をモニタリングした.
主要な成果:
- HDDT単独では87. 5%の有効性が示された. リバミピドを添加すると,有効性は96. 3%に増加しました.
- リバミピド強化療法は,以前に治療を受けた患者で91. 7%の有効性を示した.
- リバミピド群では有害事象が最も少ない (19. 8%).
結論:
- リバミピドで強化されたHDDT療法は,従来のビスムートによるトリプル療法と比較できます.
- 効果を確認するには,より大規模で多地域的な研究が必要である.
さらに関連する動画
関連する概念動画
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
546
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
546
Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
200
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
200
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
684
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
684
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
569
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
569
Gastritis III: Clinical Manifestations and Management
466
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
466


